Literature DB >> 10973246

Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.

D P Huynh1, K Figueroa, N Hoang, S M Pulst.   

Abstract

Instability of CAG DNA trinucleotide repeats is the mutational mechanism for several neurodegenerative diseases resulting in the expansion of a polyglutamine (polyQ) tract. Proteins with long polyQ tracts have an increased tendency to aggregate, often as truncated fragments forming ubiquitinated intranuclear inclusion bodies. We examined whether similar features define spinocerebellar ataxia type 2 (SCA2) pathogenesis using cultured cells, human brains and transgenic mouse lines. In SCA2 brains, we found cytoplasmic, but not nuclear, microaggregates. Mice expressing ataxin-2 with Q58 showed progressive functional deficits accompanied by loss of the Purkinje cell dendritic arbor and finally loss of Purkinje cells. Despite similar functional deficits and anatomical changes observed in ataxin-1[Q80] transgenic lines, ataxin-2[Q58] remained cytoplasmic without detectable ubiquitination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973246     DOI: 10.1038/79162

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  110 in total

1.  Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Authors:  E Martín-Aparicio; A Yamamoto; F Hernández; R Hen; J Avila; J J Lucas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 2.  Neurogenetics: single gene disorders.

Authors:  S-M Pulst
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

3.  Roles for gamma-aminobutyric acid in the development of the paraventricular nucleus of the hypothalamus.

Authors:  Kristy M McClellan; Matthew S Stratton; Stuart A Tobet
Journal:  J Comp Neurol       Date:  2010-07-15       Impact factor: 3.215

Review 4.  Molecular pathogenesis of spinocerebellar ataxia type 6.

Authors:  Holly B Kordasiewicz; Christopher M Gomez
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 5.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

6.  Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients.

Authors:  Georg Rüdiger Soukup; Anne-Dorte Sperfeld; Ingo Uttner; Jochen Karitzky; Albert Christian Ludolph; Jan Kassubek; Herbert Schreiber
Journal:  J Neurol       Date:  2009-07-02       Impact factor: 4.849

Review 7.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

8.  The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans.

Authors:  James F Morley; Heather R Brignull; Jill J Weyers; Richard I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

Review 9.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

10.  Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro.

Authors:  Guangbin Xia; Katherine Santostefano; Takashi Hamazaki; Jilin Liu; S H Subramony; Naohiro Terada; Tetsuo Ashizawa
Journal:  J Mol Neurosci       Date:  2012-12-09       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.